We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Tegsedi

News List

Final NICE guidance issued for Akcea’s Tegsedi pharmatimes
May 28, 2019
Akcea Therapeutics UK has announced that the National Institute for Health and Care Excellence (NICE) has published a final guideline for its nerve damage drug, Tegsedi (inotersen).
NICE rejects NHS funding for Tegsedi, Onpattro pharmatimes
December 13, 2018
The National Institute for Health and Care Excellence has issued draft guidelines rejecting NHS funding for two therapies that treat the rare inherited condition hereditary transthyretin-related amyliodsis (hATTR).
FDA Approves Tegsedi americanpharmaceuticalreview
October 12, 2018
The US Food and Drug Administration (FDA) approved Tegsedi (inotersen), an antisense oligonucleotide (ASO) that inhibits the production of the transthyretin (TTR) protein (amyloid), for the treatment of the polyneuropathy of hereditary transthyretin-media
US nod for Akcea/Ionis’ Tegsedi pharmatimes
October 11, 2018
Akcea and Ionis’ Tegsedi has won US approval for patients with hereditary transthyretin amyloidosis (hATTR), a rare disease causing build up of amyloid...
EMA recommends marketing authorisation to Tegsedi for hereditary transthyretin amyloidosis biospectrumasia
June 08, 2018
The EMA has recommended granting a marketing authorisation for Tegsedi, a medicine for the treatment of stage 1 or stage 2 polyneuropathy…